http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강우열 대한뇌졸중학회 2003 Journal of stroke Vol.5 No.1
Department of Neurology, Hallym University College of MedicineBackground : Leptin is a protein product of the ob gene which is expressed exclusively in adipose tissue cells. The aims of this study are to determine whether leptin level independently or in combination with other risk factors affects the onset of ischemic stroke and to determine the related subtypes of ischemic stroke. Methods : 109 patients with first-ever ischemic stroke and age-sex frequency matched 65 controls were included. Subtypes of ischemic stroke were classified by Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), smoking, diabetes mellitus, and hypertension were recorded. Blood samples were obtained within 24 hours of the onset. Triglyceride (TG), total cholesterol (Tchol), high-density lipoprotein cholesterol (HDL-c), low-density ipoprotein cholesterol (LDL-c), apolipoprotein A-1 (apol A-1), apolipoprotein B (apol B), fibrinogen, fasting blood sugar(FBS), and leptin were analyzed. Results : Patients with ischemic stroke had a higher rate of diabetes mellitus and ypertension than those in the control group. Furthermore, SBP, DBP, BMI, T-chol, LDL-c, Apo B, FBS, and the level of leptin in stroke victims were higher as well. In bivariate correlations between variables, high levels of leptin were associated with high BMI. High leptin levels and hypertension were significant risk factors for ischemic stroke in multivariate regression analysis. In each subtype analysis, high plasma leptin remained independent risk factor for large artery atherosclerosis (LAA) and small vessel occlusion (SVO). Conclusions : Elevated level of leptin may be an important link in the development of LAA and SVO.
강우열,박재승 한국의료복지시설학회 2000 의료·복지 건축 Vol.6 No.11
Recently According to the development of the medical technology and medical machine, People's concern with health promotion has improved. Futhermore, medical consuming pattern has significantly changed, and requires diverse health check-up services. This study represent the standards for the spatial composition and area calculation of the Health Promotion Center according to domestic situations. The present conditions and space programs of 4 general hospital's Health Promotion Centers were investigated and analyzed for this purpose. This study suggest a basic study on the architectural planning of the Health Promotion Center.
김현주,옥보람,강우열,성숙진,석경호,임미선,김신윤,윤영란 대한골대사학회 2016 대한골대사학회지 Vol.23 No.1
Background: Lipocalin-2 (LCN2), a small glycoprotein, has a pivotal role in diverse biological processes such as cellular proliferation and differentiation. We previously reported that LCN2 is implicated in osteoclast formation induced by receptor activator of nuclear factor-kappa B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). In the present study, we used a knockout mouse model to further investigate the role of LCN2 in osteoclast development. Methods: Osteoclastogenesis was assessed using primary bone marrow-derived macrophages. RANKL and M-CSF signaling was determined by immunoblotting, cell proliferation by bromodeoxyuridine (BrdU) enzyme-linked immunosorbent assay (ELISA), and apoptosis by cell death detection ELISA. Bone morphometric parameters were determined using a micro-computed tomography system. Results: Our results showed that LCN2 deficiency increases tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclast formation in vitro, a finding that reflects enhanced proliferation and differentiation of osteoclast lineage cells. LCN2 deficiency promotes M-CSF-induced proliferation of bone marrow macrophages (BMMs), osteoclast precursors, without altering their survival. The accelerated proliferation of LCN2-deficient precursors is associated with enhanced expression and activation of the M-CSF receptor, c-Fms. Furthermore, LCN2 deficiency stimulates the induction of c-Fos and nuclear factor of activated T cells c1 (NFATc1), key transcription factors for osteoclastogenesis, and promotes RANKL-induced inhibitor of kappa B (IκBα) phosphorylation. Interestingly, LCN2 deficiency does not affect basal osteoclast formation in vivo, suggesting that LCN2 might play a role in the enhanced osteoclast development that occurs under some pathological conditions. Conclusions: Our study establishes LCN2 as a negative modulator of osteoclast formation, results that are in accordance with our previous findings.
뇌졸중 환자에서 관찰되는 대뇌백질변성과 이에 관련된 위험인자
박종호,유경호,송홍기,이병철,강우열,류상효 대한신경과학회 2004 대한신경과학회지 Vol.22 No.2
Background:Cerebral white matter change (WMC) is usually seen in stroke patients. This study was aimed at determining whether there might be a relationship between the extent of WMC and whether to control hypertension or not and the frequency of previous stroke lesion. Stroke subtypes were also analyzed to elucidate WMC distribution. Methods:We investigated demographic features, vascular risk factors, subtypes, and WMC in 339 ischemic stroke patients over forty years of age who had brain MRI from the Hallym Stroke Registry between January 1998 and December 2001. In hypertension, it was divided into with therapy and with no therapy. In frequency of previous stroke lesion, we subdivided the patients into three groups by number of frequency: 0, 1, and ≥2. Stroke subtypes were classified into large artery atherosclerosis (LAA), small artery occlusion (SAO), cardioembolism (CE), and stroke of undetermined etiology (SUE). WMC was quantitatively estimated by subdividing into 5 grades (0~IV). Results:Age, female, hypertension, previous stroke lesion, and SAO correlated significantly with prevalence of WMC (p<0.001, =0.002, <0.001, <0.001 and <0.001, respectively). In hypertension, there was significant difference between normotensive and hypertensive (p=0.001). But there was no statistical difference between with therapy and with no therapy (p>0.05). In previous stroke lesion, it showed significant difference between 0 and (1 and ≥2) (p<0.001) and between 1 and ≥2 (p<0.001). In subtype, CE also correlated significantly with prevalence of WMC as well as SAO than LAA (p<0.001). Conclusions:WMC seen in patients with stroke is related with small-vessel disease and is mainly affected by age, female, hypertension, and previous stroke lesion.
차재민,김보경,권미리,이주미,옥보람,강우열,임미선,성숙진,김현주,이혜원,윤영란 대한임상약리학회 2016 Translational and Clinical Pharmacology Vol.24 No.1
We developed an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of acetaminophen concentration in human plasma. Fol-lowing protein precipitated extraction, the analytes were separated and analyzed using an UPLC-MS/MS in the multiple reaction monitoring (MRM) mode with the respective [M+H]+ ions, m/z 152.06 → 110.16 for acetaminophen and m/z 180.18 → 138.12 for phenacetin (internal standard, IS). The method showed a linear response from 1 to 100 μg/mL (r > 0.9982). The limit of quantitation for acetaminophen in plasma was 1 μg/mL. The intra- and inter-day accuracy ranged in the ranges of 94.40–99.56% and 90.00–99.20%, respectively. The intra- and inter-day precision ranged in the ranges of 2.64–10.76% and 6.84–15.83%, respectively. This method was simple, reliable, precise and accurate and can be used to determine the concentration of acetaminophen in human plasma. Fi¬nally, this fully validated method was successfully applied to a pharmacokinetic study of acetamino¬phen in healthy volunteers following oral administration.
조승일,제갈문영,옥보람,김보경,권미리,강우열,성숙진,김현주,이혜원,윤영란 대한임상약리학회 2017 Translational and Clinical Pharmacology Vol.25 No.2
This study describes the development of an analytical method to determine sumatriptan levels inhuman plasma using high performance liquid chromatography (HPLC) coupled with triple quadrupoletandem mass spectrometry (MS/MS) and its application to a pharmacokinetic study inhealthy Korean volunteers. A single 50 mg dose of sumatriptan was orally administered to twelvehealthy volunteers (nine women and three men). The HPLC-MS/MS analytical method was validatedwith respect to its specificity, linearity, sensitivity, accuracy, precision, recovery, and stability. The calibration curve was linear over a concentration range of 0.3–100 ng/mL (r > 0.999). Thelower limit of quantitation for sumatriptan in plasma was 0.3 ng/mL. The accuracy and precision ofthe analytical method were acceptable within 15% at all quality control levels. We compared plasmaconcentration-time curves as well as pharmacokinetic parameters such as the area under the curve(AUC) and maximum plasma concentration (Cmax). Both the mean AUC and Cmax of sumatriptanwere 1.56 times higher in women than in men. These differences could be largely explained by thedifference in body weight (44%) between women and men. The outcomes may provide insights intodeveloping appropriate individualized treatment strategies.